NCT01726348 - A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients | Biotech Hunter

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Human Immunodeficiency Virus-Type 1

Interventions

DRUG

No intervention

This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.